scholarly journals Oxidant stress stimulates anion secretion from the human airway epithelial cell line calu‐3: implications for cystic fibrosis lung disease

2002 ◽  
Vol 543 (1) ◽  
pp. 201-209 ◽  
Author(s):  
Elizabeth A. Cowley ◽  
Paul Linsdell
1994 ◽  
Vol 112 (1) ◽  
pp. 169-175 ◽  
Author(s):  
Anthony C. Chao ◽  
Jonathan B. Zifferblatt ◽  
John A. Wagner ◽  
Y.-J. Dong ◽  
Dieter C. Gruenert ◽  
...  

2008 ◽  
Vol 221 (3) ◽  
pp. 153-163 ◽  
Author(s):  
Shasta L. Moser ◽  
Scott A. Harron ◽  
Julie Crack ◽  
James P. Fawcett ◽  
Elizabeth A. Cowley

2003 ◽  
Vol 2 (3) ◽  
pp. 129-135 ◽  
Author(s):  
Massimo Conese ◽  
Elena Copreni ◽  
Sante Di Gioia ◽  
Pietro De Rinaldis ◽  
Ruggiero Fumarulo

2001 ◽  
Vol 280 (1) ◽  
pp. L127-L133 ◽  
Author(s):  
S. Tavakoli ◽  
M. J. Cowan ◽  
T. Benfield ◽  
C. Logun ◽  
J. H. Shelhamer

Human airway epithelial cell release of interleukin (IL)-6 in response to lipid mediators was studied in an airway cell line (BEAS-2B). Prostaglandin (PG) E2(10−7M) treatment caused an increase in IL-6 release at 2, 4, 8, and 24 h. IL-6 release into the culture medium at 24 h was 3,396 ± 306 vs. 1,051 ± 154 pg/ml (PGE2-treated cells vs. control cells). PGE2(10−7to 10−10M) induced a dose-related increase in IL-6 release at 24 h. PGF2α(10−6M) treatment caused a similar effect to that of PGE2(10−7M). PGE2analogs with relative selectivity for PGE2receptor subtypes were studied. Sulprostone, a selective agonist for the EP-3 receptor subtype had no effect on IL-6 release. 11-Deoxy-16,16-dimethyl-PGE2, an EP-2/4 agonist, and 17-phenyl trinor PGE2, an agonist selective for the EP-1 > EP-3 receptor subtype (10−6to 10−8M), caused dose-dependent increases in IL-6 release. 8-Bromo-cAMP treatment resulted in dose-related increases in IL-6 release. RT-PCR of BEAS-2B cell mRNA demonstrated mRNA for EP-1, EP-2, and EP-4 receptors. After PGE2treatment, increases in IL-6 mRNA were noted at 4 and 18 h. Therefore, PGE2increases airway epithelial cell IL-6 production and release.


2004 ◽  
Vol 287 (5) ◽  
pp. L928-L935 ◽  
Author(s):  
Zhenyue Tong ◽  
Beate Illek ◽  
Vikash J. Bhagwandin ◽  
George M. Verghese ◽  
George H. Caughey

Prostasin is a tryptic peptidase expressed in prostate, kidney, lung, and airway. Mammalian prostasins are related to Xenopus channel-activating protease, which stimulates epithelial Na+ channel (ENaC) activity in frogs. In human epithelia, prostasin is one of several membrane peptidases proposed to regulate ENaC. This study tests the hypothesis that prostasin can regulate ENaC in cystic fibrosis epithelia in which excessive Na+ uptake contributes to salt and water imbalance. We show that prostasin mRNA and protein are strongly expressed by human airway epithelial cell lines, including immortalized JME/CF15 nasal epithelial cells homozygous for the ΔF508 cystic fibrosis mutation. Epithelial cells transfected with vectors encoding recombinant soluble prostasin secrete active, tryptic peptidase that is highly sensitive to inactivation by aprotinin. When studied as monolayers in Ussing chambers, JME/CF15 cells exhibit amiloride-sensitive, transepithelial Na+ currents that are markedly diminished by aprotinin, suggesting regulation by serine-class peptidases. Overproduction of membrane-anchored prostasin in transfected JME/CF15 cells does not augment Na+ currents, and trypsin-induced increases are small, suggesting that baseline serine peptidase-dependent ENaC activation is maximal in these cells. To probe prostasin’s involvement in basal ENaC activity, we silenced expression of prostasin using short interfering RNA targeting of prostasin mRNA’s 3′-untranslated region. This drops ENaC currents to 26 ± 9% of baseline. These data predict that prostasin is a major regulator of ENaC-mediated Na+ current in ΔF508 cystic fibrosis epithelia and suggest that airway prostasin is a target for therapeutic inhibition to normalize ion current in cystic fibrosis airway.


Sign in / Sign up

Export Citation Format

Share Document